Sign in
Taking people in United StatesNo phase

Follows people with neurofibromatosis type 2 to study tumors and nerve problems

Follows people with neurofibromatosis type 2 over time with scans and checkups.

Key facts

Who runs it
National Institute of Neurological Disorders and Stroke (NINDS)
Where
Bethesda, United StatesSee the site
Trial code
Registry title
Natural History Study of Patients With Neurofibromatosis Type 2
Status
Recruiting
People taking part
269 people, planned
Started
21 Mar 2008
Type of study
Observational
Record updated
16 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 8 to 75 with neurofibromatosis type 2 (NF2). They will be followed for up to ten years with yearly check-ups and scans.

Age
8 to 75 years
Sex
All sexes can join.
Disease stage
A diagnosis of NF2, confirmed by established clinical criteria or genetic testing.
Biomarker or test result
NF2 diagnosis by clinical criteria or genetic testing.

Main reasons for not taking part

  • A clinically unstable condition, such as Class 3 congestive heart failure, severe chronic renal insufficiency or severe chronic obstructive pulmonary disease
  • Cannot have an MRI scan, for example because of an allergy to contrast agents or metal implants such as pacemakers
  • Auditory brainstem implants (ABIs) or cochlear implants not approved for NIH scanners
  • Severe chronic renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73 m2), hepatorenal syndrome or post-liver transplantation
  • Pregnant at the intake visit

The registry criteria, word for word

Show all 11 criteriaShow less

Who cannot take part

  • Cannot have an MRI scan due to an allergy or relative contraindication to MRI contrast agents, prior surgery or implant that involves metal clips or wires, which might be expected to cause tissue damage or produce image artifacts such as pacemakers, stimulators, pumps, aneurysm clips, metallic prostheses, and artificial heart valves
  • ABIs or cochlear implants are not approved by the NIH Radiology department for safe use on NIH scanners
  • Have a clinically unstable condition that precludes serial clinical and imaging evaluation (i.e. Class 3 congestive heart failure, severe chronic renal insufficiency, severe chronic obstructive pulmonary disease)
  • Have severe chronic renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73 m2), hepatorenal syndrome or post-liver transplantation
  • Are pregnant at time of intake visit (women of childbearing age will be tested with a urine pregnancy test)
  • Candidates will be excluded if they:

Other criteria

  • INCLUSION CRITERIA:; To be eligible for entry into the study, candidates must meet all the following criteria:
  • Have the diagnosis of NF2 by established clinical criteria or genetic testing
  • Be between the age of 8 and 75
  • Have the capacity to undergo serial MRI scanning of the CNS without IV sedation
  • Able to give informed consent, or have a parent able to provide informed consent if a child

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 8 and 75 years old?

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: Christina P Hayes, C.R.N.P.Taking people

About the trial

What the trial wants to find out

Objective

Read full original descriptionShow less

With this prospective natural experiment trial on neurofibromatosis type 2 (NF2) study, we hope to understand the factors leading to tumor progression and neurological disease burden in NF2.

Study Population

A total of 269 participants, ages 8-75, with a clinical or genetic diagnosis of NF2 will participate in this study.

Design

Study participants will be evaluated with a thorough physical and neurologic examination upon enrollment. This initial outpatient evaluation will include magnetic resonance imaging with contrast of brain and spine and blood collection for research use. Participants with measurable hearing will have audiology assessment performed. Participants with untreated vestibular schwannomas will have vestibular assessment performed during the initial visit. Genetic studies performed outside will be acceptable as confirmation of NF2 in enrolled patients. If needed to confirm NF2 with genetic studies, or for research purpose, whole genome/whole exome sequencing may be performed on blood obtained from subjects enrolled in this study. All participants will be evaluated by a speech language pathologist.

Subjects will be followed as outpatients for up to ten years, during which clinical, and radiologic evaluation will be performed annually. Auditory testing will be performed annually for participants with measurable hearing. Participants with initially untreated vestibular schwannomas will be followed annually with vestibular testing. Speech and swallowing reassessments will be repeated if worsening of speech or swallowing is reported. Blood will be collected at each visit for blood biomarker testing

Outcome measures

We hope to understand the biologic basis for speech and swallowing dysfunction in patients with NF2. We will study and report the strength of association of MRI findings, clinical assessments cranial nerve deficits and speech/swallowing dysfunction. We hope to

identify imaging biomarkers of hearing loss in NF2. We will attempt to discover the mode of peripheral neuropathy in patients with NF2. Lastly, we will attempt to discover previously unknown serum biomarkers associated with high tumor burden in NF2.

...

The group in the trial

  • Patients

    Patients must have the diagnosis of NF2 by established clinical criteria or genetic testing.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective Natural History Study of Patients With Neurofibromatosis Type 2 (NF2).
Plain-language title
Follows people with neurofibromatosis type 2 to study tumors and nerve problemsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT00598351, who can take part
Record updated
16 October 2026